Volume 2, Issue 3

• Depressive Symptoms in Schizophrenia Outpatients�?? Prevalence and Clinical Correlates
  Author(s): Oliver Freudenreich , Constantin Tranulis, Cori Cather , David C. Henderson, A. Eden Evins , Donald C. Goff
  • Abstract
  • PDF
• Diabetic Ketoacidosis Possibly Precipitated by Loxapine
  Author(s): Marilyn J. Miller
  • Abstract
  • PDF
• Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia
  Author(s): Virginia Stauffer , Jamie Karagianis , Virginia Sutton , Haya Ascher-Svanum , Tamas Treuer , Mauricio Silva de Lima , Tamara Ball , Vicki Poole-Hoffmann , Mauricio Tohen
  • Abstract
  • PDF
• Adverse Events Medication Treatment Costs in a Chronically, Severely Mentally Ill Forensics Population
  Author(s): Alexandria L. Fagan , Julie Cold Kissack , Bruce G. Augustin
  • Abstract
  • PDF
• Insight and Schizophrenia: orrelates, Etiology and Treatment
  Author(s): Paul H. Lysaker , Kelly D. Buck
  • Abstract
  • PDF
• Embarking into Recovery
  Author(s): Gareth Fenley
  • Abstract
  • PDF
• Successful Treatment of Megaloblastic Mania with Cobalamin in a Patient with Pernicious Anemia
  Author(s): David R. Spiegel , Stephanie West
  • Abstract
  • PDF
• Adding Aripiprazole to Clozapine
  Author(s): Andrea Post
  • Abstract
  • PDF
• Deconstructing Schizophrenia for DSM-V: Challenges for Clinical and Research Agendas
  Author(s): Joseph M. Pierre
  • Abstract
  • PDF
• An Interview with Joseph Parks, MD
  Author(s): Joseph Parks
  • Abstract
  • PDF
• Continued Interest in Developing Alpha-7 Nicotinic Agonist Drugs for Treating Cognitive Deficits in Patients with Schizophrenia
  Author(s): Peter F. Buckley
  • Abstract
  • PDF